San Antonio Breast Cancer Symposium | Conference

Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

December 14th 2019

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC

December 14th 2019

The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.

Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes

December 14th 2019

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups

December 14th 2019

The invasive disease-free survival benefit with adjuvant T-DM1 versus trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy was observed regardless of the type of neoadjuvant chemotherapy used.

Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

December 13th 2019

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect

December 13th 2019

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.

Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer

December 13th 2019

Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer

December 13th 2019

Subcutaneous trastuzumab with hyaluronidase-oysk in combination with intravenous pertuzumab and chemotherapy had a safety profile consistent with IV trastuzumab in first-line metastatic HER2-positive breast cancer treatment.

Neoadjuvant Durvalumab Regimen Shows Promise in TNBC

December 13th 2019

A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.

Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

December 13th 2019

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.

Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer

December 13th 2019

Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.

Accelerated Partial Breast Irradiation Could Replace Whole Breast Irradiation in Low-Risk Early Breast Cancer

December 13th 2019

Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.

Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC

December 13th 2019

Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.

Dual Anti-HER2 Therapy Reduces Recurrence Risk

December 13th 2019

A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC

December 13th 2019

Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,

Survival Benefit Hinted at With Durvalumab Maintenance in TNBC

December 13th 2019

Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.

Anastrozole Maintains Breast Cancer Prevention Effect in Long-Term Follow-Up

December 12th 2019

The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.

Benefit in pCR Rates Are Achieved With Pembrolizumab in Early TNBC

December 12th 2019

Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.

Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer

December 12th 2019

Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in patients with HR-positive/HER2-negative metastatic breast cancer

Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer

December 12th 2019

Rashmi K. Murthy, MD, MBE, discusses results of the HER2CLIMB trial in previously treated HER2-positive breast cancer.